论文信息 - Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). - 字舞流文

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

C. Martínez | R. García-Sanz | E. Domingo-Domènech | A. Sureda | M. Caballero | B. Sánchez‐González | F. de la Cruz | M. Moreno | J. Piñana | A. Gonzalez | G. Rodríguez | M. Canales | A. Rodríguez | M. Rodríguez-Salazar | A. Gutiérrez | J. López | S. Jimenez-Cabrera | A. Gonzalez